



Note

Anidulafungin versus fluconazole in the treatment of *Candida albicans* chorioretinitis



Celia Ruiz-Arranz ^{a,*}, Eugenio Pérez-Blázquez ^{a,b}, Almudena De Pablo-Cabrera ^a, Manuel Ferro-Osuna ^{a,b}

^a Department of Ophthalmology, University Hospital 12 de Octubre, Madrid, Spain

^b Faculty of Medicine, Complutense University of Madrid, Spain

ARTICLE INFO

Article history:

Received 2 February 2021

Accepted 21 May 2021

Available online 14 November 2021

Keywords:

Anidulafungin

Fluconazole

Endophthalmitis

Chorioretinitis

Candidiasis

Funduscopy

ABSTRACT

Background: *Candida albicans* chorioretinitis is the most common cause of endogenous fungal endophthalmitis. Echinocandins are recommended as first-line therapy in the treatment of invasive candidiasis (IC), but in clinically stable patients with IC and endophthalmitis caused by *Candida* species susceptible to azole compounds these are the first-line treatment due to their better intraocular penetration.

Case report: A 42-year-old woman admitted to hospital for duodenal perforation after gastrointestinal surgery and treated with broad-spectrum antibiotics developed *C. albicans* candidemia. According to protocol, an antifungal treatment with anidulafungin was given. The patient presented no visual symptoms but on routine ophthalmoscopic examination multiple bilateral chorioretinal lesions were observed. Systemic therapy was changed to fluconazole, with good systemic and ocular results.

Conclusions: Azole compounds are the first-line therapy for endophthalmitis associated with candidemia. However, clinical guidelines often propose echinocandins as the first option for IC. In some cases, *C. albicans* chorioretinitis will require a change in the systemic treatment to assure better intraocular penetration. According to the current evidence and our own experience, routine funduscopy is not necessary in all IC patients. However, we do recommend fundus examination in patients with visual symptoms or those unable to report them (paediatric patients and patients with an altered level of consciousness), and in those who are being treated with echinocandins in monotherapy.

© 2021 Asociación Española de Micología. Published by Elsevier España, S.L.U. All rights reserved.

Anidulafungina versus fluconazol en el tratamiento de la coriorretinitis por *Candida albicans*

RESUMEN

Palabras clave:

Anidulafungina

Fluconazol

Endoftalmitis

Coriorretinitis

Candidiasis

Exploración de fondo de ojo

Antecedentes: La coriorretinitis por *Candida albicans* es la forma más frecuente de endoftalmitis endógena fúngica. En la enfermedad invasora por *Candida* (EIC), las equinocandinas son la primera opción de tratamiento, pero en pacientes con EIC clínicamente estables, con endoftalmitis y con un aislamiento de *Candida* sin resistencia a los azoles, son estos últimos los antifúngicos de elección por su mejor penetración intraocular.

Caso clínico: Se presenta el caso de una mujer de 42 años con perforación duodenal posquirúrgica, antibioterapia intravenosa de amplio espectro y candidemia por *C. albicans* bajo tratamiento con anidulafungina. Aunque no presenta alteraciones visuales, se realiza exploración rutinaria del fondo de ojo, donde se observan múltiples lesiones coriorretinianas bilaterales. Se cambia el tratamiento a fluconazol, con buena evolución sistémica y ocular.

Conclusiones: Las guías clínicas indican un tratamiento empírico inicial con equinocandinas para tratar la EIC. En caso de presentar coriorretinitis por *C. albicans* multisensible es recomendable un cambio de tratamiento a azoles sistémico para asegurar una adecuada concentración antifúngica intraocular. Con la evidencia actual y en nuestra experiencia no es necesaria la exploración rutinaria del fondo de ojo en todos

* Corresponding author.

E-mail address: celia.ruiz.arranz@hotmail.com (C. Ruiz-Arranz).

los pacientes con EIC. Esta puede reservarse a pacientes con síntomas visuales, a pacientes incapaces de referir de manera precoz cualquier síntoma (pacientes pediátricos o aquellos con el nivel de conciencia alterado), o a pacientes tratados exclusivamente con equinocandinas.

© 2021 Asociación Española de Micología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Endogenous endophthalmitis is an intraocular infection resulting from haematogenous spread of an infectious agent from a primary source. Candidemia is the most frequent cause of fungal endogenous endophthalmitis. The term "candidemia" describes the presence of *Candida* in the bloodstream, and is the cause of invasive candidiasis (IC).¹⁴ *Candida albicans* is the most frequently isolated species causing intraocular infection, but *Candida glabrata*, *Candida parapsilosis*, *Candida tropicalis* and *Candida krusei* have also been reported.^{2,6}

Candida reaches the choroid firstly, where it settles and develops a choroiditis between the 3rd and 15th day of fungemia.¹⁴ It progresses affecting the retina (chorioretinitis) and causes mild vitreous inflammation afterwards. Without treatment, it progresses to the vitreous and produces an endophthalmitis. Chorioretinitis is generally asymptomatic, except when it affects the fovea. It has bilateral involvement in 67% of the cases, with multifocal lesions in 80%.^{2,14}

A 42-year-old woman was admitted to hospital after presenting duodenal perforation secondary to endoscopic retrograde cholangiopancreatography. A wide-spectrum antibiotic therapy was started. After two weeks, the patient developed fever and hypotension. Blood culture (samples from peripheral blood and central venous catheter) yielded a *C. albicans* isolate susceptible to all the antifungals tested. Following current clinical guidelines, intravenous anidulafungin was administered (200 mg loading dose on day one, followed by 100 mg daily).

Despite being asymptomatic, a routine ophthalmoscopic examination was performed. We observed multiple, small, round, deep focal yellow-white infiltrative chorioretinal lesions in both eyes. In addition, other non-specific lesions, such as Roth spots, were found. Macular spectral-domain optical coherence tomography (SD-OCT) of the right eye showed a parafoveal chorioretinal lesion which did not involve the outer retina (Fig. 1). In view of these findings, the diagnosis of *Candida* chorioretinitis was made. Due to its better intraocular penetration, the antifungal treatment was changed to oral fluconazol (800 mg loading dose on day one, followed by 400 mg daily for one month). The patient progressed favourably.

Two months after the diagnosis all lesions had resolved with the exception of a well delimitated focal white-yellow parafoveal lesion in the right eye. One year after the diagnosis the funduscopy showed no anomalies except for the persistence of a white focal parafoveal scar in the right eye. This lesion was visible in SD-OCT as a disruption in the outer retina layers (external limiting membrane, ellipsoid and interdigitation zone), without changing the retinal pigment epithelium integrity (Fig. 2).

Discussion

Ocular candidiasis (OC) occurs in patients with known risk factors: a history of diabetes mellitus, indwelling vascular catheters, broad spectrum antimicrobials, gastrointestinal surgery, intravenous drug addiction, hematologic malignancy and




Fig. 1. Images 5 days after diagnosing the ocular involvement in the woman with disseminated candidiasis. A – Right eye retinography: multiple, small, round, yellow-white lesions with indistinct borders limited to the posterior pole, one of them in the parafoveal region (arrows). Equatorial Roth spot (white asterisk). B – Spectral Domain Optical Coherence Tomography of the right eye: mild vitritis (yellow arrow) and parafoveal chorioretinal lesion which does not affect the outer retina (red asterisk). C – Left eye retinography: multiple, small, round, yellow-white lesions with indistinct borders in the posterior pole and equatorial retina (arrows). Roth spot hemorrhage (white asterisk). D – Spectral Domain Optical Coherence Tomography of the left eye: mild vitritis (yellow arrow) and preserved foveal profile.




Fig. 2. Images one year after diagnosis. A – Right eye retinography: residual white focal parafoveal scar (white arrow), complete disappearance of the lesions. B – Enhanced depth imaging optical coherence tomography of the right eye: subfoveal disruption in the external limiting membrane, ellipsoid zone and interdigitation zone with retinal pigment epithelium integrity (red asterisk). C – Left eye retinography: normal. D – Enhanced depth imaging optical coherence tomography of the left eye: normal.

immunosuppression.^{2,3,5,6,8,14} Our patient had multiple risk factors for IC development: central venous catheter, prior gastrointestinal surgery and broad spectrum antibiotic therapy. Echinocandins (caspofungin, micafungin and anidulafungin) and azole compounds (fluconazole, voriconazole) are the antifungal drugs for treating candidemia rather than amphotericin B as they have less adverse effects.³ Echinocandins are the first-line empirical therapy both in immunocompetent and immunocompromised patients with IC.¹⁰ However, in the case of patients who are clinically stable and suffer a *Candida* infection susceptible to fluconazole (*C. glabrata* and *C. krusei*), this antifungal agent can be the first-line treatment.⁴

Therapeutic guidelines^{4,6,10} recommend systemic antifungal therapy together with frequent ophthalmic examinations in endogenous *Candida* chorioretinitis with mild vitritis. Nevertheless, echinocandins are not the first-line therapy in cases with ocular involvement.⁷ The eye is a protected environment due to the blood-retinal barrier, which prevents the intraocular penetration of multiple drugs. Echinocandins (caspofungin, micafungin and anidulafungin), with a molecular weight over 1000 Da, have difficulties breaking through the ocular barrier, unlike other antifungals like azole compounds (fluconazole and voriconazole), with a molecular weight under 400 Da.

Pharmacokinetic experimental studies in neutropenic rabbits with OC secondary to IC have shown that penetration of the anidulafungin into the vitreous humor is dose-dependent and ranges from undetectable to 0.184 g/ml. Therapeutic intravitreal concentrations can only be achieved with much higher systemic doses than those usually employed in clinical practice.^{7,9,11} On the other hand, regular azole compound doses used in IC do achieve therapeutic intraocular concentrations to inhibit the growth of *C. albicans*.^{1,12,15} For this reason, we decided to change the antifungal systemic therapy in our patient.

Current clinical guidelines of the Infectious Disease Society of America (IDSA), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), recommend a dilated fundus examination in all patients with positive fungal blood cultures, whether or not they have visual symptoms.^{4,10,16} However, recent studies show low endophthalmitis incidence rates (1.6%)^{3,10,13} and postulate that indiscriminate screening does not provide significant improvement in the follow up of these patients.^{3,5} In fact, early systemic antifungal therapy with drugs with a good vitreous penetration is thought to be enough to resolve the chorioretinitis in its initial phases, and to avoid progression to the symptomatic phase of *Candida* endophthalmitis.^{3,10,13}

Based on current evidence and on our own experience, we believe that a routine funduscopy under pharmacologic dilation of the pupil is not necessary in patients with candidemia without visual symptoms in which prompt antifungal treatment has been established. We do believe it should be performed in paediatric patients and those with an altered level of consciousness, (i.e. patients in an intensive care unit), who will be unable to report early visual symptoms, as well as patients who are being treated with echinocandins in monotherapy due to its low intraocular penetration.

Funding

None declared.

Conflict of interest

The authors declare no conflict of interest.

References

1. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. *Clin Infect Dis.* 1995;20:657–64.
2. Ambou-Frutos I, Osorio-Illas L, Lastra-Pérez L, Ramos-Bello L, Lora-Domínguez K. La endoftalmatitis endógena por *Candida*, un marcador pronóstico. *Rev Cubana Oftalmol.* 2018;31.
3. Breazzano MP, Russel Day H Jr, Bloch KC, Tanaka S, Cherney EF, Sternberg P Jr, et al. Utility of ophthalmologic screening for patients with *Candida* bloodstream infections: a systematic review. *JAMA Ophthalmol.* 2019;137:698–710.
4. Cervera C. Candidiasis invasora en el adulto. Formas clínicas y tratamiento. *Enferm Infect Microbiol Clin.* 2012;30:483–91.
5. El-Abiary M, Jones B, Williams G, Lockington D. Fundoscopy screening for intraocular *Candida* in patients with positive blood cultures—is it justified? *Eye.* 2018;32:1697–702.
6. Fan KC, Russell JF, Miller D, Flynn HW Jr. In vitro susceptibilities of vitreous *Candida* endophthalmitis isolates to newer and traditional antifungal agents. *Exp Sci.* 2019;50:513–7.
7. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in *Candida albicans* endophthalmitis. *Clin Infect Dis.* 2005;41:27–8.
8. Gluck S, Headdon WG, Tang DWS, Bastian IB, Goggin MJ, Deane AM. The incidence of ocular candidiasis and evaluation of routine ophthalmic examination in critically ill patients with candidemia. *Anaesth Intensive Care.* 2015;43:693–7.
9. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. *Antimicrob Agents Chemoter.* 2001;45:2845–55.
10. Kauffman CA, Marr KA, Baron EL. Management of candidemia and invasive candidiasis in adults [Internet]. UptoDate: Kieren A Marr. Available in: www.uptodate.com [accessed 03.07.20].
11. Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, et al. Pharmacokinetics and pharmacodynamics of anidulafungin for experimental *Candida* endophthalmitis: Insights into the utility of echinocandins for treatment of a potentially sight-threatening infection. *Antimicrob Agents Chemother.* 2013;57:281–8.
12. Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA. Treatment of ocular fungal infections with oral fluconazole. *Am J Ophthalmol.* 1995;119:477–81.
13. Paulus YM, Cheng S, Karth PA. Prospective trial of endogenous fungal endophthalmitis and choriorretinitis rates, clinical course and outcomes in patients with fungemia. *Retina-J Ret Vis Dis.* 2016;36:1357–63.
14. Pérez-Blázquez E. Importancia de la vigilancia oftalmológica durante el tratamiento de la enfermedad invasora por *Candida*. *Rev Iberoam Micol.* 2009;26:78–80.
15. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental *Candida* endophthalmitis. *Antimicrob Agents Chemoter.* 1987;31:6–10.
16. Ueda T, Takesue Y, Tokimatsu I, Miyazaki T, Nakada-Motokawa N, Nagao M, et al. The incidence of endophthalmitis or macular involvement and the necessity of a routine ophthalmic examination in patients with candidemia [Internet]. PLoS ONE. 2019;14. Available in: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0216956> [accessed 22.07.20].